Any potential partners can see we are funded to go to trial.Hi
I am pleased to advise that Patrys wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has received a $3.35 million R&D Tax Incentive Refund for the 2021/2022 financial year.With this rebate and our current cash balance, our Company can confidently advance our first deoxymabs into the clinic by the end of 2023.
We are grateful for the support of the Australian Government through this initiative, which motivates investment in Australian-led innovation.
If you have any questions, please contact our team via the details below.
Ann: Patrys Receives R&D Tax Incentive Refund, page-14
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $3.003K | 428.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 131873 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 2066479 | 11 |
View Market Depth
| Last trade - 11.55am 25/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |